Cogent Biosciences, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $7.9M | $22.5M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $269.8M | $232.7M | $173.8M | $121.6M | $55.9M | $25.7M | $43.7M |
| SG&A Expense | — | $63.6M | $43.3M | $34.4M | $26.2M | $19.6M | $17.4M | $11.0M |
| Operating Income | — | $-333.4M | $-275.9M | $-208.1M | $-147.8M | $-75.6M | $-82.2M | $-32.2M |
| Operating Margin | — | — | — | — | — | — | -1,044.3% | -143.0% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | — | — | — | — | — | — |
| Net Income | — | $-328.9M | $-255.9M | $-192.4M | $-140.2M | $-72.3M | $-74.8M | $-31.8M |
| Net Margin | — | — | — | — | — | — | -950.4% | -141.5% |
| EPS (Basic) | — | $-2.16 | $-1.94 | $-1.94 | $-1.73 | $-1.87 | $-16.17 | $-4.18 |
| EPS (Diluted) | — | $-2.16 | $-1.94 | $-1.94 | $-1.73 | $-1.87 | $-16.17 | $-4.18 |
| Shares Outstanding (Basic) | 162.3M | 128.9M | 103.9M | 79.7M | 58.7M | 38.7M | 32.3M | 7.7M |
| Shares Outstanding (Diluted) | 162.3M | 128.9M | 103.9M | 79.7M | 58.7M | 38.7M | 32.3M | 7.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |